Sofalcone for treatment of Helicobacter pylori infection.
It is difficult to regard sofalcone as a single drug for the treatment of Helicobacter pylori infection. However, sofalcone exerts multiple effects against H. pylori: it has antibacterial activity, induces morphological changes, inhibits adhesion to gastric mucin and inhibits lipolytic activity. The safety profile of sofalcone even on long-term administration is well established. Therefore, it may be possible to establish a new triple therapy for H. pylori infection using sofalcone combined with antibacterial drugs and proton pump inhibitors.
Fujioka
T
T
Second Department of Internal Medicine, Oita Medical University, Japan.
Murakami
K
K
Kubota
T
T
Kodama
R
R
Honda
S
S
Nasu
M
M
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002599:Chalcone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D047188:Chalcones; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D047188:Chalcones; C035032:sofalcone; D002599:Chalcone